GSK plc presented promising preliminary data on Arexvy vaccine for adults aged 18-49 at risk for lower respiratory tract disease. The vaccine aims to protect a wider range of adults from the serious effects of RSV.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing